This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Trebananib

Amgen, Inc.

Drug Names(s): AMG386, AMG 386

Description: AMG 386 is a recombinant Fc fusion protein containing a synthetic peptide targeting angiopoietins. AMG 386 is designed to bind angiopoietins, thereby inhibiting Tie2-dependent stimulation of endothelial cells. Angiopoietins, together with vascular endothelial growth factors (VEGFs), are key cytokines that regulate neovascularization.

Deal Structure: Dyax and Amgen
In July 2004, Dyax announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to Amgen for the discovery of human antibodies for therapeutic and diagnostic product development.

Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, product license exercise fees, clinical milestone payments, and royalties on net sales of products that may result from Amgen's use of the Dyax libraries. The agreement provides Amgen with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Amgen and Takeda
In February 2008, Amgen granted Takeda an exclusive license to develop and commercialize in Japan certain of Amgens proprietary molecules in the same indications as currently being pursued by Amgen, with the potential for additional...See full deal structure in Biomedtracker

Partners: Shire Pharmaceuticals Group PLC


Trebananib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug